Ursodeoxycholic Acid
Excessive diatery intake of calories and cholesterol should be avoided. Liver function tests and bilirubin levels should be monitored every month for three months after start of therapy. 50% of successfully treated patients will develop further gallstones within 10 yr. Pregnancy and lactation. Monitoring Parameters Monitor LFTs mthly for the 1st 3 mth and every 6 mth thereafter. Lactation: unknown if excreted in breast milk; use caution
Dissolution of cholesterol-rich gallstones, Primary biliary cirrhosis, Prevention of gallstone formation in obese patients experiencing rapid weight loss,
Acute inflammation of gallbladder or biliary tract, occlusion of biliary tract, frequent episodes of biliary colic, radio-opaque calcified gallstones, impaired contractility of gallbladder, non-functioning gallbladder, inflammatory bowel disease, hepatic and intestinal conditions interfering w/ enterohepatic recirculation of bile acids, extrahepatic and intrahepatic cholestasis, ileal resection and stoma, regional ileitis, active duodenal and gastric ulcer; acute, chronic or severe hepatic disease.
N/A
>10% Headache,Dizziness,Diarrhea,Dyspepsia,Nausea/vomiting,Back pain,Upper respiratory tract infection 1-10% Alopecia,Rash,Hyperglycemia,Flatulence,Peptic ulcer,Urinary tract infection,Leukopenia,Thrombocytopenia,Cholecystitis >1% Fatigue,Abdominal pain,Thrombocytopenia,Pruritus,Angioedema,Peripheral edema,Biliary pain
Ursodeoxycholic acid suppresses hepatic synthesis and secretion of cholesterol and also inhibits intestinal absorption of cholesterol.
Cholestyramine, charcoal and antacids may reduce effectiveness. Aluminum-based antacids may reduce absorption. Oestrogens and clofibrate may counteract effectiveness of ursodeoxycholic acid by increasing cholesterol elimination in bile. Possible increase in ciclosporin serum concentration. Decreased effectiveness of dapsone. Possible decrease in serum ciprofloxacin and nitrendipine.
N/A
Oral Dissolution of cholesterol-rich gallstones Adult: 8-12 mg/kg once daily at bedtime or in 2 divided doses continued for 3-4 mth after radiological disappearance of gallstones. Duration of treatment: Up to 2 yr. Obese patients: Up to 15 mg/kg daily. Primary biliary cirrhosis Adult: 10-16 mg/kg daily in 2-4 divided doses, may be taken once daily in the evening after the 1st 3 mth. Prophylaxis of gallstones in patients undergoing rapid weight loss Adult: 300 mg bid. Non-alcoholic fatty liver disease: 13-15 mg/kg/day;
N/A
N/A
Should be taken with food.
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.